Relochem Limited, the UK-based subsidiary of Indian drug firm Marksans Pharma Ltd, has gained Medicines and Healthcare products Regulatory Agency (MHRA) authorisation for two products - Mefenamic acid film-coated tablets in 250 mg and 500 mg.
Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve aches, especially during menstruation.
Mumbai-headquartered Marksans had, through its UK subsidiary, secured numerous MHRA authorisations this year.
They include Exemestane 25 mg film-coated tablets this month; Clonidine 100 microgram tablets and Clonidine hydrochloride 25 microgram tablets in October; Moxonidine 200 and 400 microgram tablets in September; three strengths of Metformin Hydrochloride tablets in August; Metformi Hydrochloride 500mg/ 5ml oral solution, Sennosides 7.5 mg tablets in May; and Baclofen 10mg tablets in March.
In February, it received authorisation for Ibuprofen and Paracetamol 200mg/500mg film-coated tablets.
Marksans is involved in the research, manufacturing and marketing of generic medications and has manufacturing facilities in India, the US, and the UK.
